1 ing strategy for assessing hepatotoxicity of synthetic drugs.

2 resents the first neoglycorandomization of a synthetic drug and expands our understanding of the impa

3 istinct from areas addressed by conventional synthetic drugs and drug-like molecules.

4 such as those involving the substructures of synthetic drugs and protein domains, is important in fra

5 ity sensor that recognizes a wide variety of synthetic drugs and xenobiotic agents.

6 h the broad applicability and versatility of synthetic drug delivery particles.

7                                           No synthetic drug delivery system composed of biodegradable

8 this class and of comparable activity to the synthetic drug fludarubin.

9                        As the development of synthetic drugs for the prevention of stroke has proven

10 of these processes by endogenous ligands and synthetic drugs is a poorly understood area of GPCR sign

11 erived from two sources-natural products and synthetic drug-like compounds.

12                        Finally, we show that synthetic drug-like derivatives of 24(S)-HC, which poten

13                                              Synthetic drug-like molecules that directly modulate the

14 imate protection from filovirus disease by a synthetic drug-like small molecule.

15  first example of clinical resistance to the synthetic drug linezolid which involves a natural resist

16 A, (R)-calycotomine and (R)-colchietine, the synthetic drug (R)-almorexant and the (S)-enantiomer of

17                                            A synthetic drug, T113242, activates low-density lipoprote

18             This model may aid the design of synthetic drugs targeted at this transcriptional regulat

19                                         From synthetic drugs to biodegradable plastics to the origin